A cyclooxygenase-2/prostaglandin E2 pathway augments activation-induced cytosine deaminase expression Within replicating human B cells

Journal of Immunology

Volumn 185, Issue 9, 2010, Pages 5300-5314

  Lee, Hyunjoo ^a   Trott, Joshua S ^a   Haque, Shabirul ^a   McCormick, Steven ^b   Chiorazzi, Nicholas ^a,c   Mongini, Patricia K A ^a,c  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; BUTAPROST; COMPLEMENT COMPONENT C3D; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOSINE DEAMINASE; IMMUNOGLOBULIN G; INTERLEUKIN 4; MESSENGER RNA; PROSTAGLANDIN E2; AICDA (ACTIVATION INDUCED CYTIDINE DEAMINASE); AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); CYTIDINE DEAMINASE; PTGS2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL CULTURE; CELL CYCLE; CELL DEATH; CELL DIVISION; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; INFLAMMATION; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; SUPPLEMENTATION; BIOSYNTHESIS; HUMAN; IMMUNOBLOTTING; IMMUNOLOGY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

B-LYMPHOCYTES; CYCLOOXYGENASE 2; CYTIDINE DEAMINASE; DINOPROSTONE; HUMANS; IMMUNOBLOTTING; LYMPHOCYTE ACTIVATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 78149475282     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000574     Document Type: Article

References (102)

1. North, T. E., W. Goessling, C. R. Walkley, C. Lengerke, K. R. Kopani, A. M. Lord, G. J. Weber, T. V. Bowman, I. H. Jang, T. Grosser, et al. 2007. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447:1007-1011.
2. Harris, R. E. 2009. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17:55-67.
3. Ryan, E. P., S. J. Pollock, T. I. Murant, S. H. Bernstein, R. E. Felgar, and R. P. Phipps. 2005. Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J. Immunol. 174:2619-2626.
4. Bernard, M. P., and R. P. Phipps. 2007. CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: implications for adjuvant activity and antibody production. Clin. Immunol. 125:138-148.
5. Mongini, P. K., J. K. Inman, H. Han, S. L. Kalled, R. J. Fattah, and S. McCormick. 2005. Innate immunity and human B cell clonal expansion: effects on the recirculating B2 subpopulation. J. Immunol. 175:6143-6154.
6. Mongini, P. K., J. K. Inman, H. Han, R. J. Fattah, S. B. Abramson, and M. Attur. 2006. APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2. J. Immunol. 176:6736-6751.
7. Bancos, S., M. P. Bernard, D. J. Topham, and R. P. Phipps. 2009. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell. Immunol. 258:18-28.
8. Ryan, E. P., C. M. Malboeuf, M. Bernard, R. C. Rose, and R. P. Phipps. 2006. Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. J. Immunol. 177:7811-7819.
9. Bernard, M. P., S. Bancos, T. J. Chapman, E. P. Ryan, J. J. Treanor, R. C. Rose, D. J. Topham, and R. P. Phipps. 2010. Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection. Vaccine 28:1363-1372
10. Roper, R. L., B. Graf, and R. P. Phipps. 2002. Prostaglandin E2 and cAMP promote B lymphocyte class switching to IgG1. Immunol. Lett. 84:191-198.
11. Roper, R. L., D. H. Conrad, D. M. Brown, G. L. Warner, and R. P. Phipps. 1990. Prostaglandin E2 promotes IL-4-induced IgE and IgG1 synthesis. J. Immunol. 145:2644-2651.
12. Roper, R. L., and R. P. Phipps. 1992. Prostaglandin E2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgG1 synthesis. J. Immunol. 149:2984-2991.
13. He, X., C. M. Weyand, J. J. Goronzy, W. Zhong, and J. M. Stuart. 2002. Bidirectional modulation of T cell-dependent antibody production by prostaglandin E (2). Int. Immunol. 14:69-77.
14. Sun, J. H., K. K. Das, P. S. Amenta, K. Yokota, J. Watari, T. Sato, Y. Kohgo, and K. M. Das. 2006. Preferential expression of cyclooxygenase-2 in colonicphenotype of gastric intestinal metaplasia: association with helicobacter pylori and gastric carcinoma. J. Clin. Gastroenterol. 40:122-128.
15. Singh-Ranger, G., M. Salhab, and K. Mokbel. 2008. The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res. Treat. 109:189-198.
16. Babbage, G., C. H. Ottensmeier, J. Blaydes, F. K. Stevenson, and S. S. Sahota. 2006. Immunoglobulin heavy chain locus events and expression of activationinduced cytidine deaminase in epithelial breast cancer cell lines. Cancer Res. 66:3996-4000.
17. Komori, J., H. Marusawa, T. Machimoto, Y. Endo, K. Kinoshita, T. Kou, H. Haga, I. Ikai, S. Uemoto, and T. Chiba. 2008. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 47:888-896.
18. Hussain, S. P. 2008. Inflammation and cancer: is AID aiding? Gastroenterology 135:736-737.
19. Matsumoto, Y., H. Marusawa, K. Kinoshita, Y. Endo, T. Kou, T. Morisawa, T. Azuma, I. M. Okazaki, T. Honjo, and T. Chiba. 2007. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat. Med. 13:470-476.
20. Chan-On, W., K. Kuwahara, N. Kobayashi, K. Ohta, T. Shimasaki, B. Sripa, C. Leelayuwat, and N. Sakaguchi. 2009. Cholangiocarcinomas associated with long-term inflammation express the activation-induced cytidine deaminase and germinal center-associated nuclear protein involved in immunoglobulin V-region diversification. Int. J. Oncol. 35:287-295.
21. Kou, T., H. Marusawa, K. Kinoshita, Y. Endo, I. M. Okazaki, Y. Ueda, Y. Kodama, H. Haga, I. Ikai, and T. Chiba. 2007. Expression of activationinduced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int. J. Cancer 120:469-476.
22. Han, C., J. Leng, A. J. Demetris, and T. Wu. 2004. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2- independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 64:1369-1376.
23. Breinig, M., P. Schirmacher, and M. A. Kern. 2007. Cyclooxygenase-2 (COX-2) - a therapeutic target in liver cancer? Curr. Pharm. Des. 13:3305-3315.
24. Müller-Decker, K., and G. Fürstenberger. 2007. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol. Carcinog. 46:705-710.
25. Cervello, M., and G. Montalto. 2006. Cyclooxygenases in hepatocellular carcinoma. World J. Gastroenterol. 12:5113-5121.
26. Hatakeyama, M., and T. Brzozowski. 2006. Pathogenesis of Helicobacter pylori infection. Helicobacter 11 (Suppl 1):14-20.
27. Endo, Y., H. Marusawa, T. Kou, H. Nakase, S. Fujii, T. Fujimori, K. Kinoshita, T. Honjo, and T. Chiba. 2008. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology 135:889-898.e3.
28. Vincent, C., V. Truffinet, R. Fiancette, B. Petit, N. Cogné, M. Cogné, and Y. Denizot. 2009. Uncoupling between Ig somatic hypermutation and oncogene mutation in mouse lymphoma. Biochim. Biophys. Acta 1793:418-426.
29. Takaishi, S., and T. C. Wang. 2007. Providing AID to p53 mutagenesis. Nat. Med. 13:404-406.
30. Nilsen, H., Q. An, and T. Lindahl. 2005. Mutation frequencies and AID activation state in B-cell lymphomas from Ung-deficient mice. Oncogene 24:3063-3066.
31. Robbiani, D. F., S. Bunting, N. Feldhahn, A. Bothmer, J. Camps, S. Deroubaix, K. M. McBride, I. A. Klein, G. Stone, T. R. Eisenreich, et al. 2009. AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol. Cell 36:631-641.
32. Xu, W., P. A. Santini, A. J. Matthews, A. Chiu, A. Plebani, B. He, K. Chen, and A. Cerutti. 2008. Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J. Immunol. 181:276-287.
33. Rush, J. S., M. Liu, V. H. Odegard, S. Unniraman, and D. G. Schatz. 2005. Expression of activation-induced cytidine deaminase is regulated by cell division, providing a mechanistic basis for division-linked class switch recombination. Proc. Natl. Acad. Sci. USA 102:13242-13247.
34. Castigli, E., S. A. Wilson, S. Scott, F. Dedeoglu, S. Xu, K. P. Lam, R. J. Bram, H. Jabara, and R. S. Geha. 2005. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201:35-39.
35. Gourzi, P., T. Leonova, and F. N. Papavasiliou. 2007. Viral induction of AID is independent of the interferon and the Toll-like receptor signaling pathways but requires NF-kappaB. J. Exp. Med. 204:259-265.
36. Dedeoglu, F., B. Horwitz, J. Chaudhuri, F. W. Alt, and R. S. Geha. 2004. Induction of activation-induced cytidine deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NFkappaB. Int. Immunol. 16:395-404.
37. Endo, Y., H. Marusawa, K. Kinoshita, T. Morisawa, T. Sakurai, I. M. Okazaki, K. Watashi, K. Shimotohno, T. Honjo, and T. Chiba. 2007. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 26:5587-5595.
38. Schmedtje, J. F., Jr., Y. S. Ji, W. L. Liu, R. N. DuBois, and M. S. Runge. 1997. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 272:601-608.
39. Crofford, L. J., B. Tan, C. J. McCarthy, and T. Hla. 1997. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum. 40:226-236.
40. D'Acquisto, F., T. Iuvone, L. Rombolà, L. Sautebin, M. Di Rosa, and R. Carnuccio. 1997. Involvement of NF-kappaB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett. 418:175-178.
41. Basu, U., J. Chaudhuri, C. Alpert, S. Dutt, S. Ranganath, G. Li, J. P. Schrum, J. P. Manis, and F. W. Alt. 2005. The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. Nature 438:508-511.
42. McBride, K. M., A. Gazumyan, E. M. Woo, V. M. Barreto, D. F. Robbiani, B. T. Chait, and M. C. Nussenzweig. 2006. Regulation of hypermutation by activation-induced cytidine deaminase phosphorylation. Proc. Natl. Acad. Sci. USA 103:8798-8803.
43. Pasqualucci, L., Y. Kitaura, H. Gu, and R. Dalla-Favera. 2006. PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells. Proc. Natl. Acad. Sci. USA 103:395-400.
44. Narumiya, S., Y. Sugimoto, and F. Ushikubi. 1999. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79:1193-1226.
45. Regan, J. W. 2003. EP2 and EP4 prostanoid receptor signaling. Life Sci. 74:143-153.
46. Fedyk, E. R., and R. P. Phipps. 1996. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc. Natl. Acad. Sci. USA 93:10978-10983.
47. Fedyk, E. R., J. M. Ripper, D. M. Brown, and R. P. Phipps. 1996. A molecular analysis of PGE receptor (EP) expression on normal and transformed B lymphocytes: coexpression of EP1, EP2, EP3beta and EP4. Mol. Immunol. 33:33-45.
48. Ishikawa, T. O., N. Jain, and H. R. Herschman. 2009. Feedback regulation of cyclooxygenase-2 transcription ex vivo and in vivo. Biochem. Biophys. Res. Commun. 378:534-538.
49. Faour, W. H., Y. He, Q. W. He, M. de Ladurantaye, M. Quintero, A. Mancini, and J. A. Di Battista. 2001. Prostaglandin E (2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J. Biol. Chem. 276:31720-31731.
50. Liang, X., Q. Wang, J. Shi, L. Lokteva, R. M. Breyer, T. J. Montine, and K. Andreasson. 2008. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann. Neurol. 64:304-314.
51. Kojima, F., H. Naraba, Y. Sasaki, M. Beppu, H. Aoki, and S. Kawai. 2003. Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum. 48:2819-2828.
52. Sagana, R. L., M. Yan, A. M. Cornett, J. L. Tsui, D. A. Stephenson, S. K. Huang, B. B. Moore, M. N. Ballinger, J. Melonakos, C. D. Kontos, et al. 2009. Phosphatase and tensin homologue on chromosome 10 (PTEN) directs prostaglandin E2-mediated fibroblast responses via regulation of E prostanoid 2 receptor expression. J. Biol. Chem. 284:32264-32271.
53. Mongini, P. K., M. A. Vilensky, P. F. Highet, and J. K. Inman. 1997. The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J. Immunol. 159:3782-3791.
54. Chen, K., W. Xu, M. Wilson, B. He, N. W. Miller, E. Bengtén, E. S. Edholm, P. A. Santini, P. Rath, A. Chiu, et al. 2009. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cellstimulating programs in basophils. Nat. Immunol. 10:889-898.
55. Ittah, M., C. Miceli-Richard, J. Eric Gottenberg, F. Lavie, T. Lazure, N. Ba, J. Sellam, C. Lepajolec, and X. Mariette. 2006. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res. Ther. 8: R51.
56. Mongini, P. K., C. A. Blessinger, P. F. Highet, and J. K. Inman. 1992. Membrane IgM-mediated signaling of human B cells. Effect of increased ligand binding site valency on the affinity and concentration requirements for inducing diverse stages of activation. J. Immunol. 148:3892-3901.
57. Wu, X., J. R. Darce, S. K. Chang, G. S. Nowakowski, and D. F. Jelinek. 2008. Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells. Blood 112:4675-4682.
58. Mongini, P. K., W. E. Paul, and E. S. Metcalf. 1983. IgG subclass, IgE, and IgA anti-trinitrophenyl antibody production within trinitrophenyl-Ficoll- responsive B cell clones. Evidence in support of three distinct switching pathways. J. Exp. Med. 157:69-85.
59. Longo, N. S., P. L. Lugar, S. Yavuz, W. Zhang, P. H. Krijger, D. E. Russ, D. D. Jima, S. S. Dave, A. C. Grammer, and P. E. Lipsky. 2009. Analysis of somatic hypermutation in X-linked hyper-IgM syndrome shows specific deficiencies in mutational targeting. Blood 113:3706-3715.
60. Zan, H., A. Cerutti, P. Dramitinos, A. Schaffer, Z. Li, and P. Casali. 1999. Induction of Ig somatic hypermutation and class switching in a human monoclonal IgM+ IgD+ B cell line in vitro: definition of the requirements and modalities of hypermutation. J. Immunol. 162:3437-3447.
61. Subbaramaiah, K., K. Yoshimatsu, E. Scherl, K. M. Das, K. D. Glazier, D. Golijanin, R. A. Soslow, T. Tanabe, H. Naraba, and A. J. Dannenberg. 2004. Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J. Biol. Chem. 279:12647-12658.
62. Samuelsson, B., R. Morgenstern, and P. J. Jakobsson. 2007. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 59:207-224.
63. Kojima, F., M. Kapoor, L. Yang, E. L. Fleishaker, M. R. Ward, S. U. Monrad, P. C. Kottangada, C. Q. Pace, J. A. Clark, J. G. Woodward, and L. J. Crofford. 2008. Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice. J. Immunol. 180:8361-8368.
64. Katada, J., H. Saito, and A. Ohashi. 2005. Significance of cyclooxygenase-2 induced via p38 mitogen-activated protein kinase in mechanical stimulusinduced peritoneal adhesion in mice. J. Pharmacol. Exp. Ther. 313:286-292.
65. Rajagopalan, G., Y. W. Asmann, A. K. Lytle, A. Y. Tilahun, J. E. Theuer, M. K. Smart, R. Patel, and C. S. David. 2008. Cyclooxygenase 2 pathway and its therapeutic inhibition in superantigen-induced toxic shock. Shock 30:721-728.
66. Dorsett, Y., K. M. McBride, M. Jankovic, A. Gazumyan, T. H. Thai, D. F. Robbiani, M. Di Virgilio, B. R. San-Martin, G. Heidkamp, T. A. Schwickert, et al. 2008. MicroRNA-155 suppresses activation-induced cytidine deaminasemediated Myc-Igh translocation. Immunity 28:630-638.
67. Blaho, V. A., M. W. Buczynski, E. A. Dennis, and C. R. Brown. 2009. Cyclooxygenase-1 orchestrates germinal center formation and antibody classswitch via regulation of IL-17. J. Immunol. 183:5644-5653.
68. Sugimoto, Y., and S. Narumiya. 2007. Prostaglandin E receptors. J. Biol. Chem. 282:11613-11617.
69. Xu, Z., E. J. Pone, A. Al-Qahtani, S. R. Park, H. Zan, and P. Casali. 2007. Regulation of aicda expression and AID activity: relevance to somatic hypermutation and class switch DNA recombination. Crit. Rev. Immunol. 27:367-397.
70. Basu, U., A. Franklin, B. Schwer, H. L. Cheng, J. Chaudhuri, and F. W. Alt. 2009. Regulation of activation-induced cytidine deaminase DNA deamination activity in B-cells by Ser38 phosphorylation. Biochem. Soc. Trans. 37:561-568.
71. Mongini, P. K., K. E. Stein, and W. E. Paul. 1981. T cell regulation of IgG subclass antibody production in response to T-independent antigens. J. Exp. Med. 153:1-12.
72. Garrone, P., L. Galibert, F. Rousset, S. M. Fu, and J. Banchereau. 1994. Regulatory effects of prostaglandin E2 on the growth and differentiation of human B lymphocytes activated through their CD40 antigen. J. Immunol. 152:4282-4290.
73. Jelinek, D. F., P. A. Thompson, and P. E. Lipsky. 1985. Regulation of human B cell activation by prostaglandin E2. Suppression of the generation of immunoglobulin-secreting cells. J. Clin. Invest. 75:1339-1349.
74. Tanaka, T., X. Huang, H. D. Halicka, H. Zhao, F. Traganos, A. P. Albino, W. Dai, and Z. Darzynkiewicz. 2007. Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A 71:648-661.
75. Zaheen, A., B. Boulianne, J. Y. Parsa, S. Ramachandran, J. L. Gommerman, and A. Martin. 2009. AID constrains germinal center size by rendering B cells susceptible to apoptosis. Blood 114:547-554.
76. Hubbard, N. E., S. Lee, D. Lim, and K. L. Erickson. 2001. Differential mRNA expression of prostaglandin receptor subtypes in macrophage activation. Prostaglandins Leukot. Essent. Fatty Acids 65:287-294.
77. Ackerman, W. E., 4th, T. L. Summerfield, D. D. Vandre, J. M. Robinson, and D. A. Kniss. 2008. Nuclear factor-kappa B regulates inducible prostaglandin E synthase expression in human amnion mesenchymal cells. Biol. Reprod. 78:68-76.
78. Sernández, I. V., V. G. de Yébenes, Y. Dorsett, and A. R. Ramiro. 2008. Haploinsufficiency of activation-induced deaminase for antibody diversification and chromosome translocations both in vitro and in vivo. PLoS ONE 3: e3927.
79. Takizawa, M., H. Tolarová, Z. Li, W. Dubois, S. Lim, E. Callen, S. Franco, M. Mosaico, L. Feigenbaum, F. W. Alt, et al. 2008. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J. Exp. Med. 205:1949-1957.
80. Phillips, C. 1989. Prostaglandin E2 production is enhanced in mice genetically selected to produce high affinity antibody responses. Cell. Immunol. 119:382-392.
81. Roper, R. L., D. M. Brown, and R. P. Phipps. 1995. Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE. J. Immunol. 154:162-170.
82. Fujino, H., S. Salvi, and J. W. Regan. 2005. Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol. Pharmacol. 68:251-259.
83. Chio, C. C., Y. H. Chang, Y. W. Hsu, K. H. Chi, and W. W. Lin. 2004. PKA-dependent activation of PKC, p38 MAPK and IKK in macrophage: implication in the induction of inducible nitric oxide synthase and interleukin-6 by dibutyryl cAMP. Cell. Signal. 16:565-575.
84. Minamizaki, T., Y. Yoshiko, K. Kozai, J. E. Aubin, and N. Maeda. 2009. EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures. Bone 44:1177-1185.
85. Côté, S. C., S. Pasvanis, S. Bounou, and N. Dumais. 2009. CCR7-specific migration to CCL19 and CCL21 is induced by PGE (2) stimulation in human monocytes: Involvement of EP (2)/EP (4) receptors activation. Mol. Immunol. 46:2682-2693.
86. Chen, B. C., C. C. Liao, M. J. Hsu, Y. T. Liao, C. C. Lin, J. R. Sheu, and C. H. Lin. 2006. Peptidoglycan-induced IL-6 production in RAW 264.7 macrophages is mediated by cyclooxygenase-2, PGE2/PGE4 receptors, protein kinase A, I kappa B kinase, and NF-kappa B. J. Immunol. 177:681-693.
87. Kim, R. J., H. A. Kim, J. B. Park, S. R. Park, S. H. Jeon, G. Y. Seo, D. W. Seo, S. R. Seo, G. T. Chun, N. S. Kim, et al. 2007. IL-4-induced AID expression and its relevance to IgA class switch recombination. Biochem. Biophys. Res. Commun. 361:398-403.
88. Yamada, T., K. Zhang, A. Yamada, D. Zhu, and A. Saxon. 2005. B lymphocyte stimulator activates p38 mitogen-activated protein kinase in human Ig class switch recombination. Am. J. Respir. Cell Mol. Biol. 32:388-394.
89. Van den Berghe, W., S. Plaisance, E. Boone, K. De Bosscher, M. L. Schmitz, W. Fiers, and G. Haegeman. 1998. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factorkappaB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273:3285-3290.
90. Clark, A. R., J. L. Dean, and J. Saklatvala. 2009. The p38 MAPK pathway mediates both antiinflammatory and proinflammatory processes: comment on the article by Damjanov and the editorial by Genovese. Arthritis Rheum. 60:3513-3514.
91. Dean, J. L., M. Brook, A. R. Clark, and J. Saklatvala. 1999. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J. Biol. Chem. 274:264-269.
92. Frasca, D., A. M. Landin, R. L. Riley, and B. B. Blomberg. 2008. Mechanisms for decreased function of B cells in aged mice and humans. J. Immunol. 180:2741-2746.
93. Pesu, M., S. Aittomäki, K. Takaluoma, A. Lagerstedt, and O. Silvennoinen. 2002. p38 Mitogen-activated protein kinase regulates interleukin-4-induced gene expression by stimulating STAT6-mediated transcription. J. Biol. Chem. 277:38254-38261.
94. Ghosh, S., and D. Baltimore. 1990. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature 344:678-682.
95. Aoufouchi, S., A. Faili, C. Zober, O. D'Orlando, S. Weller, J. C. Weill, and C. A. Reynaud. 2008. Proteasomal degradation restricts the nuclear lifespan of AID. J. Exp. Med. 205:1357-1368.
96. Krysan, K., F. H. Merchant, L. Zhu, M. Dohadwala, J. Luo, Y. Lin, N. Heuze-Vourc'h, M. Põld, D. Seligson, D. Chia, et al. 2004. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J. 18:206-208.
97. Kato, T., H. Kutsuna, N. Oshitani, and S. Kitagawa. 2006. Cyclic AMP delays neutrophil apoptosis via stabilization of Mcl-1. FEBS Lett. 580:4582-4586.
98. Zhang, L., A. M. Bertucci, K. A. Smith, L. Xu, and S. K. Datta. 2007. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus. Arthritis Rheum. 56:4132-4141.
99. Cha, S., E. Singson, J. Cornelius, J. P. Yagna, H. J. Knot, and A. B. Peck. 2006. Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjögren's syndrome-associated autoantibodies. J. Rheumatol. 33:296-306.
100. Mariette, X. 2001. Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann. Rheum. Dis. 60:1007-1010.
101. Tapinos, N. I., M. Polihronis, and H. M. Moutsopoulos. 1999. Lymphoma development in Sjögren's syndrome: novel p53 mutations. Arthritis Rheum. 42:1466-1472.
102. Jiang, C., M. L. Zhao, and M. Diaz. 2009. Activation-induced deaminase heterozygous MRL/lpr mice are delayed in the production of high-affinity pathogenic antibodies and in the development of lupus nephritis. Immunology 126:102-113.